Dupilumab in Adults With Moderate to Severe Atopic Dermatitis: A 5-Year Open-Label Extension Study.

ABSTRACT:

Importance

Moderate to severe atopic dermatitis (AD) is a chronic inflammatory skin disease that often requires continuous long-term systemic management. Long-term safety and efficacy data for treatment options are critically important.

Objective

To assess the safety and efficacy of dupilumab treatment for up to 5 years in adults with moderate to severe AD.

Design, setting, and participants

The 5-year LIBERTY AD open-label extension study was conducted from September 2013 to June 2022 at 550 sites in 28 countries. The study enrolled adult patients with moderate to severe AD who had participated in previous dupilumab clinical trials. Data were analyzed from August 2022 to February 2023.

Exposures

At enrollment, patients initiated a regimen of subcutaneous dupilu

SUBMITTER: Beck LA 

PROVIDER: S-EPMC11238067 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature